Characteristics | All trials | Type of Intention-to-treat reporting N (%) | ||
---|---|---|---|---|
 | N = 367 | ITT 197 (54) | mITT 56 (15) | 'no ITT' 114 (31) |
Journal | Â | Â | Â | Â |
Medical journals | 200 (55) | 123 (62) | 33 (59) | 44 (38) |
Specialty journals | 167 (45) | 74 (38) | 23 (41) | 70 (61) |
Study design features | Â | Â | Â | Â |
Phase II | 13 (4) | 7 (4) | 1 (2) | 5 (4) |
Equivalence/Noninferiority | 31 (8) | 14 (7) | 9 (13) | 10 (9) |
Sample size [median, (IQR)] | 368 (140-991) | 476 (200-1160) | 426 (198-1093) | 201 (81-620) |
Trials with post-randomization exclusions | 177 (48) | 84 (43) | 37 (66) | 56 (49) |
Proportion of post-randomization exclusions [median, (IQR)] | 4 (1-11) | 3 (1-11) | 4 (1-10) | 5 (3-12) |
Placebo use | 123 (34) | 51 (26) | 27 (48) | 45 (40) |
Reporting and Quality assessment | Â | Â | Â | Â |
Flow chart | 222 (60) | 137 (70) | 37 (66) | 48 (42) |
Reporting of sample size calculation | 285 (78) | 172 (87) | 42 (79) | 69 (61) |
Reporting of lost to follow-up/withdrawal | 211 (57) | 127 (64) | 35 (63) | 49 (43) |
Adequate sequence generation | 167 (46) | 108 (55) | 21 (39) | 38 (33) |
Adequate allocation concealment | 125 (34) | 78 (40) | 22 (39) | 25 (22) |
Adequate blinding | 110 (30) | 57 (29) | 25 (45) | 28 (25) |
Funding | Â | Â | Â | Â |
Not-for-profit organization | 137 (37) | 88 (45) | 9 (16) | 40 (35) |
For-profit agency | 121 (33) | 52 (26) | 40 (71) | 32 (28) |
Co-financed | 66 (18) | 42 (21) | 5 (9) | 19 (17) |
Not reported | 43 (12) | 18 (9) | 2 (4) | 23 (20) |
Author's conflict of interest | Â | Â | Â | Â |
Author declaring no competing interests | 113 (31) | 74 (38) | 8 (14) | 31 (27) |
Author on behalf of a for-profit agency | 143 (39) | 70 (36) | 40 (71) | 33 (29) |
Author disclosing other financial ties | 61 (17) | 42 (21) | 3 (5) | 16 (15) |
No report of competing interests | 50 (14) | 11 (6) | 5 (9) | 34 (30) |
Primary Outcome | Â | Â | Â | Â |
Favorable to test drug | 216 (60) | 110 (56) | 38 (70) | 68 (60) |